Senators don’t believe that Valeant Pharmaceuticals has changed its ways when it comes to charging high prices for its products.
“Valeant and its shareholders may have changed its tune in recent months, but make no mistake,” said Sen. Claire McCaskill, D-Mo., during a hearing of the Senate Special Committee on Aging Thursday.
Stay informed.Stay ahead.
Join Washington Examiner for unlimited access to the news, analysis, and commentary that matter most.
See Options
Already a member? Log in
Already a print subscriber? Click here to login/register your account
